'''

How My AI Startup Almost Died Before We Pivoted to a $10M Niche in Drug Discovery

We were three weeks from payroll and had about $52,000 left in the bank. I remember the exact number because I stared at it for about an hour, just watching the cursor blink. My co-founder, a brilliant PhD from Stanford who could make a neural network sing, was whiteboarding some insane new architecture. He was oblivious. I was about to throw up.

This was my third startup. The first two had successful exits. I was supposed to be the guy who knew what he was doing. I’d invested in over 200 companies, including some of the biggest names in AI like Anthropic and OpenAI. Yet here I was, about to crater my own company and lay off 12 people I’d convinced to leave their cushy jobs at Google and Apple.

Most founders in my position would start cutting costs, desperately trying to extend the runway by a few more weeks. They’d be sending out frantic emails to their investor network, begging for a bridge round. I’d been there before. It’s a slow, painful death.

We didn’t do that. We killed our product instead.

The Seductive Lie of the "Better Model"

Our first idea was brilliant, or so we thought. We were building a generalized AI platform for hospitals. We had a model that could predict patient readmission rates with 92% accuracy, identify early signs of sepsis from EHR data, and even optimize operating room schedules. It was a technical marvel. We had the charts to prove it. We’d raised a $3 million seed round on the back of a demo that made seasoned healthcare executives gasp.

And it was a complete and utter failure.

We spent 18 months trying to sell it. The sales cycle was brutal. We’d spend six months in a pilot program, get amazing results, and then… nothing. The hospital administrators would congratulate us, talk about the "potential," and then ghost us for the next six months. They loved the tech, but they couldn’t figure out how to buy it, how to integrate it, or who was even supposed to own it.

We were selling a solution to a problem they didn’t know they had. The uncomfortable truth that most AI founders refuse to accept is this: a better model is not a business.

I see this constantly with the companies I advise. They come to me with these incredibly sophisticated models, convinced they’re going to change the world. They’ve spent all their time and money on the tech, and almost none on the brutal, unsexy work of figuring out who the customer is and what they will actually pay for.

The Pivot That Saved Us

I called an all-hands meeting. I put our bank balance on the main screen. The room went silent. My co-founder stopped whiteboarding.

"We

're done," I said. "The product is dead. We're starting over. And we have three weeks to find a new direction before the money runs out."

You could have heard a pin drop. Then came the questions, the arguments, the fear. But underneath it all, there was a flicker of something else: relief. We all knew, deep down, that we were pushing a boulder uphill. Now, at least, we had a chance to find a better hill.

We turned our office into a war room. The whiteboards were covered not with model architectures, but with problems. We listed every single painful, expensive, soul-crushing problem we could find in the healthcare industry. We called every doctor, every hospital administrator, every pharma exec in our contact lists. We didn’t pitch them. We just asked them: "What’s the stupidest, most expensive, most manual process you have to deal with every day?"

From Hospital Chaos to a $10M Niche

For two weeks, we heard an earful. We learned about billing nightmares, scheduling disasters, and the eternal hell of prior authorizations. The problems were huge, but so were the moats. The incumbents were massive, and the sales cycles were still a decade long.

Then, on a Wednesday afternoon, I got a call back from a friend of a friend who was a VP of preclinical research at a mid-sized pharmaceutical company. I had left him a voicemail. I almost didn’t answer the phone.

"Sahin," he said, "you asked for my most expensive problem. It’s target validation. We spend millions, sometimes tens of millions, betting on a biological target for a new drug, only to find out 18 months later in a clinical trial that we were wrong. It kills the drug, wastes years of work, and costs a fortune."

I felt a jolt. This was different. This wasn’t a vague, system-wide problem. It was specific. It was measurable. And it was incredibly expensive.

"What if," I asked, my heart starting to pound, "what if we could use AI to predict the likelihood of a target succeeding before you spend millions on it? What if we could analyze genomic data, existing research, and molecular interactions to give you a probability score?"

There was a pause on the other end of the line. "If you could do that," he said slowly, "and prove it works? I’d pay you a million dollars a year for it. And I know at least ten other companies that would too."

That was it. That was our $10 million niche.

Building for a Customer, Not a Conference

We threw everything we had at this single problem. We took our core modeling expertise, but instead of applying it to the messy, chaotic data of a hospital system, we pointed it at the structured, high-dimensional data of genomics and proteomics. We weren’t building a general platform anymore. We were building a very specific, very powerful tool for a very specific user: the drug discovery scientist.

Three weeks later, we had a prototype. It was ugly. The UI was a mess. But it did one thing: it took a proposed drug target and spat out a validation score. We showed it to our pharma contact. He gave us a small, anonymized dataset to test it on. Our model correctly identified the two targets in that set that had eventually failed in Phase II trials.

He signed a letter of intent for a $500,000 pilot project the next day.

That $500k was our lifeline. It got us to our next milestone, and six months later, we closed a $15 million Series A led by the venture arm of that same pharmaceutical company. We’re not a generalized AI platform anymore. We’re a clinical AI company that helps pharma companies make better bets. And we’re on track to do $8 million in revenue this year.

The Lessons I Etched Into My Brain

Looking back, the near-death experience was the best thing that ever happened to us. It forced us to confront the lies we were telling ourselves. Here’s what I learned:

• Your Model is a Commodity. Someone else, somewhere, is building a model that’s just as good as yours, or will be soon. Your technology is not your moat. Your deep understanding of a customer’s pain is your moat.

• Go for the Jugular. Don’t solve a nice-to-have problem. Find the most painful, expensive, hair-on-fire problem you can and solve that. In healthcare, that means following the money. Who stands to lose millions if this problem isn’t solved? That’s your buyer.

• Niches are Empires. The temptation is to build a huge, world-changing platform. Resist it. Find a tiny, underserved niche and dominate it. Become the undisputed best in the world at solving one specific problem for one specific customer. That’s how you build an empire.

• Kill Your Darlings. Don’t be afraid to throw away your product, your code, your entire roadmap. The only thing that matters is finding product-market fit. Be loyal to the problem, not your solution.

I still have that screenshot of our bank account with $52,000 in it. It’s a reminder that the difference between a dead startup and a thriving one isn’t a better algorithm. It’s a brutal, relentless focus on a customer’s pain. Stop trying to build a better model and start trying to solve a real problem.

The Unsexy Work is the Real Work

I want to linger on this for a moment, because it’s the part that nobody wants to talk about in Silicon Valley. We celebrate the visionaries, the product geniuses, the 10x engineers. We don’t celebrate the person who spends three days cleaning a dataset or the sales executive who gets told “no” 100 times to get one “maybe.”

When we pivoted, 80% of our work wasn’t building AI. It was doing the grunt work that made the AI possible. My co-founder, the Stanford PhD, spent a week manually labeling genomic data. Not because he had to, but because he needed to understand its nuances, its flaws, its hidden structures. We built custom scripts to scrape data from obscure academic journals. We spent hours on the phone with lab technicians to understand their exact workflow, not the idealized version in a textbook.

This is the reality of building a successful AI company in a regulated, complex field like healthcare. It’s not about having the fanciest algorithm. It’s about having the best data, and the best data comes from doing the hard, manual, unsexy work of understanding the real world. You have to earn your right to automate.

We also had to become experts in things that had nothing to do with code. We learned about the intricacies of intellectual property in drug discovery. We learned how to structure a pilot study to deliver the exact evidence a pharma company needed to make a multi-million dollar decision. We learned to speak the language of biochemists and clinical researchers, translating our model’s outputs into insights they could act on.

This is the moat. It’s not the code; the code is open source. It’s the thousand small, painful lessons you learn by immersing yourself in your customer’s world. It’s the custom data pipelines you build, the proprietary datasets you clean by hand, the trust you earn by showing up and doing the work.

The Future is Specific

I get pitched by AI founders every single day. They all tell me they’re building the next great AI platform. They show me demos that can write, or draw, or code. I’m rarely impressed.

I’m not looking for a platform. I’m looking for a scalpel. I’m looking for a team that has found a single, high-value problem and has gone deeper on it than anyone else in the world. A team that is obsessed with their customer’s pain.

We almost died because we fell in love with the elegance of our technology. We were saved when we fell in love with our customer’s ugly, expensive, complicated problem. The future of AI in healthcare won’t be about horizontal platforms that do everything. It will be about vertical solutions that do one thing perfectly.

So if you’re an AI founder, I urge you, stop polishing your model and go talk to a customer. Better yet, go work alongside them. Find a problem so painful they’d pay almost anything to solve it. Then, and only then, should you start writing code. The world doesn’t need another AI demo. It needs solutions. And solutions are built on a foundation of empathy, not just algorithms.

Frequently Asked Questions

What experience informs this perspective?

This perspective comes from over a decade of building companies in Silicon Valley, two successful exits (RemoteTeam to Gusto, MovieLaLa to Gfycat), and investing in 200+ startups including Anthropic, OpenAI, and Scale AI. I write about what I've lived.

Do all experts agree with this view?

No, and that's fine. The best ideas in business are often contrarian. I share my perspective based on my experience and data, but I encourage you to seek out opposing viewpoints and form your own conclusions.

What's the most common pushback you get on this?

People often push back by citing exceptions or edge cases. And they're usually right that exceptions exist. But building a strategy around exceptions rather than patterns is a losing game for most founders.

How can I apply this thinking to my own situation?

Start by identifying the core principle behind the opinion, not the specific example. Then ask yourself: does this principle apply to my context? If yes, test it in a small, low-risk way before going all in.